These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 32551974)

  • 1. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
    Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
    Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime.
    Bomsztyk J; Ravichandran S; Khwaja J; Cohen O; Rauf MU; Foard D; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore J; Lachmann H; Mahmood S; Wechalekar AD
    Br J Haematol; 2024 Jul; 205(1):138-145. PubMed ID: 38840512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
    Kastritis E; Dialoupi I; Gavriatopoulou M; Roussou M; Kanellias N; Fotiou D; Ntanasis-Stathopoulos I; Papadopoulou E; Ziogas DC; Stamatelopoulos K; Manios E; Ntalianis A; Eleutherakis-Papaiakovou E; Papanikolaou A; Migkou M; Papanota AM; Gakiopoulou H; Psimenou E; Tselegkidi MI; Tsitsilonis O; Kostopoulos I; Terpos E; Dimopoulos MA
    Blood Adv; 2019 Oct; 3(20):3002-3009. PubMed ID: 31648323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes.
    Diaz-Pallares C; Lee H; Luider J; Duggan P; Neri P; Tay J; MacCulloch S; Bahlis NJ; Jimenez-Zepeda VH
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):394-399. PubMed ID: 32146104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.
    Dima D; Hughes M; Orland M; Ullah F; Goel U; Anwer F; Raza S; Mazzoni S; Bhutani D; Williams L; Lentzsch S; Samaras C; Valent J; Chakraborty R; Khouri J
    Amyloid; 2024 Sep; 31(3):195-201. PubMed ID: 38956891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
    Adam Z; Stork M; Pour L; Krejčí M; Zahradová L; Sandecká V; Hájek R; Cermáková Z; Pospíšilová Y; Navrátil M; Král Z; Mayer J
    Vnitr Lek; 2012 Dec; 58(12):896-903. PubMed ID: 23427947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.
    Leung N; Thomé SD; Dispenzieri A
    Haematologica; 2018 Mar; 103(3):e135-e137. PubMed ID: 29351984
    [No Abstract]   [Full Text] [Related]  

  • 11. Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14).
    Ghilardi G; Stussi G; Mazzucchelli L; Röcken C; Rossi D; Gerber B
    Amyloid; 2019 Sep; 26(3):173-174. PubMed ID: 31232114
    [No Abstract]   [Full Text] [Related]  

  • 12. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
    Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
    N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?
    Yip PL; Lau JSM; Lam CP
    Int J Hematol; 2020 Aug; 112(2):234-237. PubMed ID: 32207051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
    Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
    Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab Plus Bortezomib and Dexamethasone in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Kennedy VE; Natsuhara K; Maringanti SA; Shah ND; Arora S; Wolf J; Martin TG; Aras MA; Chung A; Wong SW
    Curr Probl Cancer; 2023 Jun; 47(3):100953. PubMed ID: 36807996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
    Kastritis E; Leleu X; Arnulf B; Zamagni E; Cibeira MT; Kwok F; Mollee P; Hájek R; Moreau P; Jaccard A; Schönland SO; Filshie R; Nicolas-Virelizier E; Augustson B; Mateos MV; Wechalekar A; Hachulla E; Milani P; Dimopoulos MA; Fermand JP; Foli A; Gavriatopoulou M; Klersy C; Palumbo A; Sonneveld P; Johnsen HE; Merlini G; Palladini G
    J Clin Oncol; 2020 Oct; 38(28):3252-3260. PubMed ID: 32730181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival.
    Venner CP; Lane T; Foard D; Rannigan L; Gibbs SD; Pinney JH; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Blood; 2012 May; 119(19):4387-90. PubMed ID: 22331187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
    Brennan X; Withers B; Jabbour A; Milliken S; Kotlyar E; Fay K; Ma D; Muthiah K; Hamad N; Dodds A; Bart N; Keogh A; Hayward C; Macdonald P; Moore J
    Intern Med J; 2022 Oct; 52(10):1826-1830. PubMed ID: 36266066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.